Fisher & Paykel Healthcare Corporation Limited (NZSX:FPH, ASX:FPH) announced today that it intends to release on Friday, 25 May its financial results for the year ended 31 March 2012. The release will be issued shortly after 9:00am NZST, 7:00am AEST (5:00pm USEDT, Thursday, 24 May).
Fisher & Paykel Healthcare will host a conference call on Friday, 25 May to review the results and to discuss the outlook for the 2013 financial year. The conference call is scheduled to begin at 10:00am NZST, 8:00am AEST (6:00pm USEDT, Thursday, 24 May) and will be broadcast simultaneously over the Internet.
To listen to the webcast access the company’s website at www.fphcare.com. Please allow extra time prior to the webcast to visit the site and download the streaming media software if required. An online archive of the event will be available approximately two hours after the webcast and will remain on the site for two weeks. To attend the conference call, participants will need to dial in to one of the numbers below at least 5 minutes prior to the scheduled call time and identify yourself to the operator. When prompted, please quote the conference code of: 76732439
New Zealand Toll Free 0800 452 569 USA Toll Free 1866 242 1388 Australia Toll Free 1800 354 715 Hong Kong Toll Free 800 968831 United Kingdom Toll Free 0808 234 7860 International +61 2 8823 6760
An audio replay of the conference call will be available approximately 2 hours after the call and will be accessible for two weeks by dialing one of the numbers below. When prompted please enter the conference code of: 76732439.
New Zealand Toll Free 0800 445 136 USA Toll Free 1866 214 5335 Australia Toll Free 1800 766 700 Hong Kong Toll Free 800 901596 United Kingdom Toll Free 0800 731 7846 International +61 2 8235 5000
About Fisher & Paykel Healthcare Fisher & Paykel Healthcare is a leading designer, manufacturer and marketer of products and systems for use in respiratory care, acute care and the treatment of obstructive sleep apnea. The company’s products are sold in more than 120 countries worldwide. For more information about the company, visit our website www.fphcare.com.
Contact: Michael Daniell MD/CEO on +64 9 574 0161 or Tony Barclay CFO on +64 9 574 0119.
Full Year Results to be announced on 25 May 2012
Find clinical evidence and practice guidelines for delivering nasal high flow (aka HFNC) therapy.
Providing Optimal Humidity for intubated patients
Featuring under nose NIV masks (F&P Visairo) and full face NIV masks - (F&P Nivairo), with vented and non-vented options to suit your hospital NIV mask needs.
Establish effective spontaneous breathing or assist ventilation of the lungs
Respiratory support that replaces spontaneous breathing
Noninvasive respiratory support that provides a continuous distending pressure
Noninvasive respiratory support that delivers high flows of blended air and oxygen
Designed to work in harmony with the way patients naturally breathe while they sleep
F&P SleepStyle - designed to strike the balance between comfort and effective treatment
We value your privacy. Our websites and applications use cookies to function properly and securely.